Laboratory animals as surrogate models of human obesity.
Obesity and obesity-related metabolic diseases represent a growing socioeconomic problem throughout the world. Great emphasis has been put on establishing treatments for this condition, including pharmacological intervention. However, there are many obstacles and pitfalls in the development process from pre-clinical research to the pharmacy counter, and there is no certainty that what has been observed pre-clinically will translate into an improvement in human health. Hence, it is important to test potential new drugs in a valid translational model early in their development. In the current mini-review, a number of monogenetic and polygenic models of obesity will be discussed in view of their translational character.
Diabetes Research Unit, Novo Nordisk A/S, Beijing Novo Nordisk Pharmaceuticals Sci & Tech Co Ltd., Beijing, China.
Cecilia
C
Nilsson
Kirsten
K
Raun
Fei-fei
FF
Yan
Marianne O
MO
Larsen
Mads
M
Tang-Christensen
D000818:Animals; D004032:Diet; D004195:Disease Models, Animal; D006801:Humans; D051379:Mice; D009765:Obesity / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D051381:Rats; D057170:Translational Research, Biomedical / Q000379:methods